Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK16149 in orthopedic perioperative analgesia
NCT06007066Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of crisugabalin besilate in postoperative pain (5 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Morphine Consumption at 24 hours. Started Mar 2023; status: completed.
02
Drugs
crisugabalin besilate
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06007066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007066.